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Carotid Plaque Hemorrhage on Magnetic
Resonance Imaging Strongly Predicts
Recurrent Ischemia and Stroke
Akram A. Hosseini, MRCP, MD,1 Neghal Kandiyil, MRCS,1,2 Shane T.
S. MacSweeney, FRCS, MChir,2 Nishath Altaf, FRCS, PhD,1,2 and Dorothee
P. Auer, FRCR, PhD1
Objective: There is a recognized need to improve selection of patients with carotid artery stenosis for carotid endar-
terectomy (CEA). We assessed the value of magnetic resonance imaging (MRI)-defined carotid plaque hemorrhage
(MRIPH) to predict recurrent ipsilateral cerebral ischemic events, and stroke in symptomatic carotid stenosis.
Methods: One hundred seventy-nine symptomatic patients with 50% stenosis were prospectively recruited, under-
went carotid MRI, and were clinically followed up until CEA, death, or ischemic event. MRIPH was diagnosed if the
plaque signal intensity was >150% that of the adjacent muscle. Event-free survival analysis was done using Kaplan–
Meier plots and Cox regression models controlling for known vascular risk factors. We also undertook a meta-analysis
of reported data on MRIPH and recurrent events.
Results: One hundred fourteen patients (63.7%) showed MRIPH, suffering 92% (57 of 62) of all recurrent ipsilateral
events and all but 1 (25 of 26) future strokes. Patients without MRIPH had an estimated annual absolute stroke risk
of only 0.6%. Cox multivariate regression analysis proved MRIPH as a strong predictor of recurrent ischemic events
(hazard ratio [HR]512.0, 95% confidence interval [CI]54.8–30.1, p<0.001) and stroke alone (HR5 35.0, 95%
CI5 4.7–261.6, p50.001). Meta-analysis of published data confirmed this association between MRIPH and recurrent
cerebral ischemic events in symptomatic carotid artery stenosis (odds ratio5 12.2, 95% CI5 5.5–27.1, p< 0.00001).
Interpretation: MRIPH independently and strongly predicts recurrent ipsilateral ischemic events, and stroke alone, in
symptomatic 50% carotid artery stenosis. The very low stroke risk in patients without MRIPH puts into question cur-
rent risk–benefit assessment for CEA in this subgroup.
ANN NEUROL 2013;73:774–784
The efficacy of carotid endarterectomy (CEA) in sec-ondary prevention of stroke in patients with sympto-
matic severe carotid artery stenosis is well documented
by pooled randomized controlled trial evidence.1 Current
guidelines recommend early surgical intervention for
symptomatic individuals with 50 to 99% carotid stenosis
as determined by angiographic or ultrasonographic mea-
surement of the luminal diameter according to the North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) criteria.2 However, 70 to 80% of sympto-
matic patients with 50% stenosis will not experience
recurrent stroke at 5 years.3,4 This group of patients at
low risk of recurrent cerebral ischemic events routinely
undergo potentially unnecessary surgical intervention,
demonstrating the limitation of the current risk stratifica-
tion model, based on degree of stenosis alone.5
Randomized controlled trials were mostly per-
formed more than a decade ago, since which time there
has been considerable progress in best medical manage-
ment for secondary prevention of stroke. Since then, the
EXPRESS study has successfully changed clinical practice
to early initiation of medical therapy after transient ische-
mic attack (TIA) or minor stroke, lowering the risk of
stroke recurrence.6 This improvement in medical treat-
ment may also reduce the additional benefit from sur-
gery. Nonetheless, some recent guidelines recommend
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expanding the indications for carotid revascularization in
carotid disease.7 A cost-effective and reliable method of
defining stroke risk beyond that predicted by the degree
of stenosis alone would offer the potential to better target
patients most likely to benefit from surgery, while avoid-
ing unnecessary surgery for those at low risk of embolic
stroke from carotid disease.
Detection of ultrasonographic microembolic signals
by transcranial Doppler can be used to assess patients at
high risk of recurrence,8 but has a limited power in accu-
rately identifying those at very low risk who may be
safely excluded from carotid intervention. Other research
efforts focused on noninvasive imaging techniques to
predict the “vulnerable” or “unstable” plaque based on
the evidence that certain histomorphological plaque fea-
tures are associated with symptomatic carotid disease.9
Atherosclerotic plaque destabilization is histologically
characterized by fibrous cap rupture, high lipid content,
and notably, intraplaque hemorrhage.10,11 Recently devel-
oped dedicated magnetic resonance imaging (MRI) tech-
niques allow characterization of these features,12 of which
intraplaque hemorrhage (PH) is the most widely studied
imaging marker. Based on typical MRI characteristics of
blood products, PH can be reliably identified in both
multicontrast and single T1-weighted MRI scans that
depict PH as distinct intraplaque hyperintensity.13–16
MRI-defined PH (MRIPH) accurately predicts the
histologically defined vulnerable plaque (type VI athero-
sclerotic plaque as defined by the American Heart Associa-
tion).15 Conversely, MRIPH was shown to be associated
with previous, acute, or recent ipsilateral cerebral
infarcts,17–21 acute and chronic cerebral ischemic lesion
burden,22,23 and accelerated recurrent ipsilateral cerebral
infarction.24 It may also indicate accelerated plaque
growth.25,26 The notion that MRIPH may be considered
a marker of thromboembolic plaque activity was under-
pinned by its association with microembolic signals during
CEA,27 and with spontaneous microembolic signals.23
Further support comes from an association of MRIPH
with acute diffusion abnormalities, and in particular with
multiple diffusion abnormalities of multiple ages indexing
recurrent recent embolic events.23 Importantly, MRIPH
may predict recurrence and incidence of cerebrovascular
ischemic events, such as stroke, TIA, or amaurosis fugax
(AmF) in both symptomatic and asymptomatic carotid
artery stenosis.19,24,28–34 It is however still unclear whether
MRIPH can predict recurrent stroke alone, which would
need to be demonstrated before MRIPH could be used
for risk stratification and selection criteria for invasive
therapy. Moreover, the reported studies are limited in sam-
ple size and observed events, which led to inaccurate esti-
mates of the predictive power of MRIPH.
Before the implementation of fast-track surgical
intervention, we undertook several prospective MRIPH
studies in patients with significant symptomatic carotid
artery disease. Their clinical management followed best
clinical practice at the time of recruitment, so that CEA
was performed later and possibly less frequently than in
today’s practice. Based on this pool of data, we were able
to build the largest and arguably a unique longitudinal
MRIPH study in patients with symptomatic moderate to
severe carotid disease (50–99%). The aim of this
extended follow-up study was to determine the predictive
value of MRIPH for better stroke risk stratification. To
achieve this, we assessed (1) whether MRIPH independ-
ently predicts ipsilateral stroke, (2) how strongly MRIPH
predicts all recurrent ipsilateral ischemic events, and (3)
the annual risk of recurrent events in patients without
MRIPH. We then performed a systematic review and
meta-analysis of published data on the predictive value of
MRIPH.
Patients and Methods
Study Population
The study population included the pooled data from 3 prospec-
tive single-center observational studies undertaken between Oc-
tober 2002 and September 2009 following identical
recruitment protocols and procedures as previously
described30,31,35 with new extended follow-up. All patients were
consecutively identified from TIA clinics or vascular clinics at
the Queen’s Medical Centre, Nottingham. Initial cerebral ische-
mic events including hemispheric TIA, AmF, or nondisabling
stroke were confirmed by a clinical consultant or fellow with
special interest in stroke medicine or vascular surgery. Partici-
pants were recruited into the study if they had had an ischemic
event within the previous 6 months, no contraindications to
MRI, and a life expectancy of >2 years.
Clinical treatment and all clinical follow-up assessments
were performed blinded to the results of the carotid MRI.
Imaging Protocol
As part of clinical care, all participants had undergone carotid
Doppler ultrasonography prior to recruitment. Subjects with
50% stenosis were recruited, provided their index cerebrovas-
cular ischemic event was ipsilateral to the carotid artery disease.
The degree of stenosis was graded by using ultrasound criteria
adapted from the angiographic measurements of the North
American Symptomatic Carotid Surgery Trial as used in the
Carotid and Vertebral Artery Transluminal Angioplasty Study.36
If carotid Doppler was unable to estimate reliably the degree of
stenosis, magnetic resonance angiography was performed.
At entry to the study, consenting participants were
assessed for cardiovascular risk factors and underwent brain
MRI, performed on 1 of the following 1.5T scanners: Vision
(Siemens Healthcare, Erlangen, Germany), Intera (Philips Med-
ical Systems, Best, the Netherlands), or Signa (General Electric,
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Milwaukee, WI), using standard receive-only quadrature neck
array coils, as described previously.30,31,35 All patients under-
went a coronal T1-weighted 3-dimensional gradient echo
sequence with effective blood nulling and fat suppression due
to selective water excitation (repetition time5 10.3 millisec-
onds, echo time5 4.0 milliseconds, Flip angle5 15, inversion
time5 20 milliseconds, field of view5 350 3 300mm,
matrix5 256 3 140, 140 partitions, volume thickness5 120–
150mm). The acquisition took <5 minutes.
The images were recorded for offline image analysis,
which was performed using standard image reconstruction tech-
niques as provided by Jim (Xinapse Systems, www.xinapse.com)
software. Presence of carotid PH was determined by 2 trained
researchers (N.A., N.K.) and adjudicated by an experienced
neuroradiologist (D.P.A.), all blinded to the clinical data.
Although the presence of PH is readily detectable in the vast
majority of cases (Fig 1), the classification used for this study
was based on the ratio of the signal intensity within the most
hyperintense plaque component relative to that of adjacent ster-
nocleidomastoid muscle; a ratio >1.5 was defined as MRIPH1,
and 1.5 as MRIPH2. We have previously shown an excellent
interobserver agreement (Cohen j5 0.80–0.88).31
Clinical Assessment and Follow-up
Clinical assessments for any cerebrovascular ischemic event
(stroke, TIA, or AmF), cardiovascular risk factors, and medica-
tions were recorded at the time of recruitment. Follow-up until
occurrence of ipsilateral ischemic symptom (primary endpoint)
or terminating points was performed by the same researcher for
each individual study. All recurrent ischemic events were veri-
fied by review of clinical details, and all strokes were confirmed
as ischemic by neuroimaging.
Coded data from all 3 studies were pooled for new
extended follow-up performed by an independent blinded
researcher with training experience in neurology/stroke
(A.A.H.), which was in part (26 of 62 cerebrovascular events)
reported in Kandiyil et al.35 Case notes and the hospital Intra-
net system for central medical records were reviewed to verify
clinical index presentation events and any new ipsilateral cere-
bral ischemic events (TIA, AmF, or stroke) or terminating
points until October 2011. In addition, new atrial fibrillation
at the time of recurrent event, contralateral stroke, and myocar-
dial infarction were recorded over the entire follow-up period
that ranged from 1 day up to 9 years (1–3,344 days).
All patients gave written informed consent for the origi-
nal studies as approved by the local ethics committee and
research and development department, both of which approved
the pooled analysis for extended follow-up.
Statistical Analysis
We investigated whether the presence of MRIPH predicted ipsi-
lateral ischemic stroke, and separately all ischemic events (TIA,
AmF, or stroke) by using Kaplan–Meier survival analysis and
log-rank test. Ischemic event rates per 100 person-years were
calculated for each outcome, and the formula annual
risk5 12 (exp [2event rate 3 time]) was used to estimate the
absolute annual risk. Time to event was further analyzed for
stroke and all ipsilateral ischemic events by use of univariate
and multivariate Cox regression analysis for MRIPH and estab-
lished vascular risk factors including age, sex, diabetes mellitus,
hypertension, lipid-lowering drugs, antiplatelet therapy, ische-
mic heart disease, smoking habit, and degree of ipsilateral ca-
rotid stenosis, applying a backward conditional model. To
assess whether MRIPH is a nonspecific marker of vascular risk
rather than a direct marker of the vulnerability of the affected
carotid plaque, we also assessed whether MRIPH predicts myo-
cardial infarction or contralateral stroke using a backward con-
ditional Cox regression model adjusted for sex and degree of
carotid stenosis.
Lastly, as the chosen carotid MRI does not allow direct
differentiation between intraplaque hemorrhage and associated
luminal thrombus, we explored the time dependence of
MRIPH in relation to the presenting symptom using regression
analysis. All tests were performed using SPSS for Windows
(version 18.0; SPSS, Chicago, IL); p< 0.05 was considered
significant.
FIGURE 1: Axial views of T1-weighted water-selective magnetic resonance imaging to detect plaque hemorrhage of carotid
arteries. Hyperintense signals (B–D, white arrows) reflect plaque hemorrhage in carotid arteries, black arrows (A) show absence
of plaque hemorrhage, and asterisks indicate the lumen of internal carotid artery. (A) No signal hyperintensity. (B) Large mod-
erately hyperintense plaque. (C) Small strongly hyperintense plaque. (D) Large strongly hyperintense plaque.
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Meta-Analysis
We performed a meta-analysis combining the results from our
pooled data with those from other studies that reported the
relationship between the presence of MRIPH and ipsilateral
cerebral ischemic events including both symptomatic and
asymptomatic carotid artery disease. PubMed and Embase were
searched between January 1990 and April 2012. Search terms
were [TIA OR transient isch(a)emic attack OR amaurosis fugax
OR stroke OR cerebral isch(a)emi(*) OR cerebral infarct(*)]
AND (*)plaque AND carotid(*). Only articles written in Eng-
lish and reporting results in humans were included. Reference
lists of selected articles were also searched for relevant referen-
ces. Case series and individual case reports were excluded. The
inclusion criteria took in symptomatic or asymptomatic carotid
artery stenosis using MRI carotid plaque imaging techniques in
which hyperintense signal reflected vulnerable carotid plaque.
Studies using T2-weighted MRI and contrast-enhanced mag-
netic resonance angiogram were examined and excluded due to
lack of histological validation studies and the likelihood of rep-
resenting lipid-enriched plaque components other than PH.
Studies providing data on cerebral ischemic events prior to the
plaque imaging were excluded. Two researchers (A.A.H.,
D.P.A.) independently extracted data from each study. Meta-
analysis was performed using RevMan5 software (Cochrane
IMS, ims.cochrane.org) by use of a random effect model.37
Results
We included 179 subjects with symptomatic carotid
artery disease with 50% on the standard ultrasound cri-
teria described in Patients and Methods. This included
127 (70.9%) men and 52 (29.1%) women with a mean
age of 71.7 years (range5 41–91, interquartile
range5 65–79 years). A total of 114 subjects (63.7%)
were identified to have MRIPH (MRIPH1). MRIPH
was absent (MRIPH2) in the remaining 65 patients.
Demographic characteristics and risk factors in the study
population with or without MRIPH are provided in
Table 1. Patients with PH were more likely to be male
(as previously reported35) and non- or ex-smokers and
tended to be less affected by ischemic heart disease (see
Table 1). Time from presenting symptom did not affect
presence of MRIPH (p5 0.65).
We observed 62 recurrent ipsilateral ischemic events
during the follow-up; 57 of these occurred in the
MRIPH1 subgroup (25 ischemic strokes, 23 TIAs, and
9 AmFs), compared with only 5 ischemic events (1
stroke, 2 TIAs, and 2 AmFs) in the MRIPH2 group (Ta-
ble 2). Myocardial infarction or contralateral strokes was
seen in 18 patients (12 MRIPH1, 6 MRIPH2). New
atrial fibrillations were noted in 3 patients at the time of
recurrent event (all MRIPH2).
Kaplan–Meier survival analysis demonstrated signif-
icantly shorter stroke-free survival for the MRIPH1
compared with MRIPH2 group (overall chi-
square5 28.3, df5 1, p< 0.001; Fig 2A). Univariate
Cox regression analysis for stroke confirmed MRIPH to
significantly increase the risk of future ipsilateral ischemic
stroke (hazard ratio [HR]5 33.7, 95% confidence inter-
val [CI]5 4.5–251.3, p5 0.001). Applying backward
conditional modeling, adjusted for known vascular risk
factors and time from indexed symptoms to MRI,
revealed MRIPH as the only significant factor to predict
recurrent stroke (HR5 35.0, 95% CI5 4.7–261.6,
p5 0.001). Similarly, Kaplan–Meier survival analysis
illustrated remarkably different survival curves of partici-
pants remaining free of all ipsilateral cerebral ischemic
events between those with or without MRIPH (overall
chi-square5 41.7, df5 1, p< 0.001; see Fig 2B).
Univariate Cox regression confirmed MRIPH to
notably increase the risk of any future cerebrovascular ische-
mic events (HR5 11.5, 95% CI5 4.6–28.9, p< 0.001).
Using backward conditional analysis, only 2 factors showed
significant association with recurrent cerebral ischemic
events: presence of MRIPH (HR5 12.0, 95% CI5 4.8–
30.1, p< 0.001) and the degree of stenosis, that is, high-
degree (70–99%) stenosis versus moderate-degree (50–
69%) stenosis (HR5 1.9, 95% CI5 1.1–3.3, p5 0.016).
Applying backward conditional Cox regression
showed that MRIPH did not pose a significant risk of
contralateral stroke or myocardial infarction during the
follow-up period (p5 0.95).
Kaplan–Meier analysis of the 2 subgroups classified by
luminal narrowing, moderate- versus high-degree stenosis,
demonstrated that the presence of MRIPH clearly predicted
recurrent ipsilateral events in both moderate-degree (50–
69%) and high-degree (70–99%) stenosis (chi-
square5 42.1, df5 1, p< 0.001; see Fig 2C, D).
The estimated risk of any ipsilateral ischemic event
at 5 years in 50% symptomatic carotid stenosis was sig-
nificantly higher in MRIPH1 compared with MRIPH2
patients (85.3%, 95% CI5 74.7–95.9 vs 13.2%, 95%
CI5 1.1–25.3, p< 0.001). The risk difference between
those with and without MRIPH for recurrent stroke was
114.9%, 150.9%, and 166.8% at years 1, 3, and 5,
respectively (Table 3).
For the systematic review and meta-analysis, we
identified 3,764 PubMed and 2,771 Embase abstracts.
Only 9 papers provided subsequent recurrent ischemic
events for their study population. Of these, 2 articles were
our own partially published data and were omitted to
avoid duplication.30,31 One paper that met our inclusion
criteria did not disclose the relevant raw data,34 and was
therefore excluded. A total of 6 studies in addition to this
study incorporating data from previous publications30,31
met the criteria for full or partial data extraction for the
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TABLE 1. Demographic Characteristics and Risk Factors in Participants with and without PH on Ipsilateral Ca-
rotid MRI at the Time of Recruitment into the Study
Characteristic MRIPH1,
n5 114
MRIPH2,
n5 65
p
Age, median yr (interquartile range) 74.9 (66–79) 73.8 (62–785) 0.1
Female, No. [%] 25 [21.9] 27 [41.5] 0.001a
Diabetes mellitus, No. [%] 14 [12.3] 6 [9.2] 0.53
Hypertension, No. [%] 91 [79.8] 51 [78.5] 0.66
Ischemic heart disease, No. [%] 28 [24.6] 22 [33.8] 0.09
Statin use, No. [%]b 88 [77.2] 52 [80] 0.44
Atrial fibrillation, No. [%] 7 [6.1] 7 [10.8] 0.13
Smoking habit, No. [%]
Smokers 39 [34] 34 [52] 0.04a
Nonsmokers 45 [40] 20 [31]
Ex-smokersc 30 [26] 11 [17]
Antiplatelet or anticoagulant agents used, No. [%] 0.32
Aspirin 73 [64] 31 [47.7]
Clopidogrel 3 [2.6] 8 [12.3]
Duald 31 [27.2] 19 [29.2]
Warfarin 6 [5.3] 4 [6.2]
None 1 [0.9] 3 [4.6]
Degree of Stenosis, No. [%]e 0.61
50–69% 43 [37.7] 25 [38.5]
70–99% 71 [62.3] 40 [61.5]
Type of symptom on presentation, No. [%] 0.72
Stroke 39 [34.2] 24 [36.9]
TIA 52 [45.6] 26 [40]
Amaurosis fugax 23 [20.2] 15 [23.1]
Time between clinic assessment and MRI, median
days (interquartile range)
16.5 (2–40.5) 27 (14.5–64) 0.65f
Time between presenting symptom and MRI,
median days (interquartile range)
36.5 (16.5–81.2) 45 (24–86.5)
Time from clinical assessment and carotid
endarterectomy, median days
34 55
Total carotid endarterectomies, No. [%] 82 [72] 38 [58]
Follow-up until terminating point, mean days
(interquartile range)g
311 (15.5–105) 924 (44.5–1,863)
Follow-up until any endpoint, mean days (interquartile range)h 303 (15–176) 880 (40.5–1,773)
New atrial fibrillation at the time of recurrent event, No. [%] 0 3 [4.6]
aSignificantly different (p< 0.05) between MRIPH1 and MRIPH2 groups.
bPatients were on regular statin therapy >6 months prior to inclusion into the study.
cEx-smokers were defined as having stopped smoking for >6 months.
dAspirin1 (dipyridamol or clopidogrel).
eBased on ultrasound criteria described in Patients and Methods.
fApplying binary regression analysis, MRIPH was used as a dependent variable, with time from index symptom to MRI as the
covariate.
gFollow-up period from the entry point until the end of the study period, ipsilateral carotid endarterectomy, or death if the patient
did not meet the primary endpoint (recurrent event).
hFollow-up until recurrent ischemic event or terminating endpoint.
MRI5magnetic resonance imaging; MRIPH25 absence of hyperintense signal on MRI; MRIPH15 presence of hyperintense
signal on MRI; PH5 intraplaque hemorrhage; TIA5 transient ischemic attack.
meta-analysis. Half the studies reported data on sympto-
matic carotid stenosis,24,28,33 and the remaining 3 had
studied asymptomatic carotid stenosis or a combination of
both symptomatic and asympotamic.19,29,32
Meta-analysis on all available data for symptomatic
patients (n5 335, 80 events in 188 MRIPH1 vs 7 events
in 147 MRIPH2) confirmed the significant predictive
value of MRIPH for ipsilateral cerebral ischemic events
(odds ratio [OR]5 12.2, 95% CI5 5.5–27.1; Fig 3).
To control for a potential bias from the effect of
the Nottingham data weight of 66%, we repeated the
meta-analysis after exclusion of Nottingham data, which
showed a similarly strong association that remained sig-
nificant (OR5 12.6, 95% CI5 3.2–49.7, p5 0.0003;
heterogeneity: I25 0%, p5 0.06).
To further explore whether MRIPH may also be a
useful risk marker for future events in asymptomatic ca-
rotid disease, we conducted a meta-analysis of all avail-
able data for patients with carotid stenosis (see Fig 3).
MRIPH was found to be associated with a significantly
higher risk of clinical recurrence or new ischemic events
in carotid artery disease (OR5 10.0, 95% CI5 5.5–
18.4, p< 0.00001; heterogeneity: I25 0%, p< 0.85).
Despite inclusion of patients with asymptomatic disease
and differences in MRI technique and degree of stenosis,
we did not see significant between-study heterogeneity
(Q stat5 1.29; p5 0.26). The published evidence from
studies in patients with asymptomatic carotid stenosis is,
however, limited (only a total of 24 events for 282
arteries), and larger cohorts with longer follow-up are
needed to confirm the predictive power of MRIPH in
asymptomatic carotid stenosis.
Discussion
We found that MRI-defined carotid plaque hemorrhage
independently and strongly predicted recurrent ipsilateral
ischemic events and stroke in patients with symptomatic
50% carotid artery stenosis. Presence of MRIPH was
associated with significantly shorter stroke- and event-free
survival using multivariate Cox regression analysis. This
translated into an estimated risk difference of 66% for
stroke at 5 years.
The strong association of MRIPH and recurrent
events makes it a promising biomarker for risk assess-
ment of recurrent events and stroke. We consider plaque
hemorrhage as detected by MRI to be a pathophysiologi-
cally plausible biomarker of the thromboembolic propen-
sity of carotid plaques. This notion is supported by the
relationship between carotid MRIPH and the presence of
ipsilateral cerebral ischemic lesion burden,22,23 microem-
bolic signals during CEA,27 and recurrent recent embolic
events as detected by multiple white matter diffusion
abnormalities as well as spontaneous microembolic sig-
nals.23 Moreover, 3-dimensional, T1-weighted, blood-
and fat-nulled MRI has been histologically qualified to
accurately detect plaque hemorrhage in our sample16 and
by others,15 with sensitivity of 91 to 100% and specific-
ity of 77 to 80%, meeting some key biomarker
requirements.
Like other biomarkers, including microembolic
signals detected by using transcranial Doppler imaging,
no direct causative link can be claimed for any given
index cerebral ischemic event. MRIPH may simply be
an index of overall cardiovascular and stroke risk.38
Nevertheless, in our study population the presence of
TABLE 2. Analysis of Recurrent Cerebral Ischemic Events in Symptomatic Patients with 50% Carotid Artery
Stenosis
Adjusted for Risk Factorsa
Events, No. PY Event Rate
per 100 PY
Annual Risk Hazard Ratio
(95% CI)
p
Ipsilateral recurrent stroke, TIA or AmF
MRIPH1 57 94.6 60.2 45.2% 11.95
(4.8–30.1)
<0.001
MRIPH2 5 156.7 3.2 3.1% 1.0
Ipsilateral recurrent stroke
MRIPH1 25 94.6 26.4 23.2% 35.0
(4.7–261.6)
0.001
MRIPH2 1 156.7 0.64 0.6% 1.0
aAdjusted for age, sex, degree of carotid stenosis, and known vascular risk factors as described in Patients and Methods.
AmF5 amaurosis fugax; CI5 confidence interval; MRI5magnetic resonance imaging; MRIPH25 absence of hyperintense signal
on MRI; MRIPH15 presence of hyperintense signal on MRI; PY5 person years; TIA5 transient ischemic attack.
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MRIPH in symptomatic carotid artery plaques did not
increase the risk of stroke in the contralateral hemi-
sphere or myocardial infarction, adding evidence for a
direct link. Arguably, demonstration of previous plaque
rupture is a risk factor for future ruptures. This does
not exclude the possibility that in some patients, MRI
signal hyperintensity may reflect a more recent intralu-
minal thrombus that may directly cause significantly
elevated risk for thromboembolic stroke. The MRI pro-
tocol with a 5-minute volume scan that was used did
not allow differentiation between plaque hemorrhage
and intraluminal thrombus, a limitation that is shared
by some histological carotid studies.38 In our patient
cohort, however, time from the index ischemic symp-
tom to MRI was relatively long (mean5 576 47 days),
which reduced the plausibility that the MRI hyperin-
tense signal reflected fresh luminal thrombus.
Furthermore, the time from indexed symptoms to MRI
did not affect the presence of MRIPH, making intralu-
minal thrombus an unlikely contribution to the
observed MRI hyperintensity.
This interpretation of MRIPH as a cumulative vul-
nerability marker would explain that the differential risk
prediction was not limited to the immediate time period
after the initial event, but preserved or even increased for
at least 5 years. Further support for the assumption that
PH is a relatively stable vulnerability marker of stroke risk
comes from longitudinal studies showing substantially sta-
ble features of MRIPH.26,39 Although this makes a direct
temporal link with recent plaque rupture unlikely, the sta-
bility of PH and its prolonged predictive power for future
events are clinically valuable properties, especially for
assessment of patients attending clinics outside of the 2-
week window that is the ideal time for intervention.
FIGURE 2: Survival analysis (Kaplan–Meier plot) figures confirm predictive value of magnetic resonance imaging–defined plaque
hemorrhage (MRIPH) for (A) stroke and (B) all cerebral ischemic events in both (C) moderate-degree carotid artery stenosis and
(D) high-degree stenosis. HR5hazard ratio.
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TABLE 3. Risk Estimation for Recurrent Ipsilateral Ischemic Events in Patients with Symptomatic Carotid Ar-
tery Stenosis in the Presence of MRIPH
MRIPH1
with
Cumulative
No. of Patients
with Event at 1
Year (at 3 years)
Cumulative
Riska at 1 Year,
% [95% CI]
Cumulative
Riska at 3
Years, %
[95% CI]
Risk Difference
vs MRIPH2
Group at
1 Year, %
Risk Difference vs
MRIPH2
Group at 3
Years, %
50% Stenosis 42/114 (53/114) 53.4%
[41.1–65.7]
76.9%
[65.3–885]
145.3 168.8
50–69% Stenosis 15/43 (24/43) 40.6% 70.7% 132.3 162.4
70–99% Stenosis 27/71 (29/71) 67.2% 83.6% 159.3 175.7
aKaplan–Meier estimate.
CI5 confidence interval; MRI5magnetic resonance imaging; MRIPH25 absence of hyperintense signal on MRI; MRIPH15 -
presence of hyperintense signal on MRI.
FIGURE 3: Meta-analysis of available studies on symptomatic carotid arteries (n5335), and symptomatic combined with
asymptomatic carotid arteries (n5667) to evaluate the association between magnetic resonance imaging (MRI) signal hyperin-
tensity and future risk of ipsilateral cerebral ischemic events. *Combined data including symptomatic carotid artery stenosis
and contralateral asymptomatic arteries. yOnly included the subgroup of patients with MRI-defined intraplaque hemorrhage
(PH) who were followed up for subsequent ischemic events. zPH1 within lipid-rich necrotic core plaque (LRNC) compared with
PH2 with LRNC; DoS5Degree of stenosis. CI5 confidence interval; ND5not disclosed in the paper.
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MRIPH was present in 63.7% of symptomatic ca-
rotid arteries in our study population of moderate and
severe carotid stenosis. This differs from other in vivo
plaque studies reporting 28% and 36.7% in 50 to 79%
and 50 to 70% asymptomatic carotid artery stenosis,
respectively.32,40 Our reported prevalence of MRIPH is,
however, in very close agreement with the 64% PH-posi-
tive findings from the Oxford Plaque Study,41 a large ca-
rotid PH examination of CEA specimens from
symptomatic carotid arteries with 70% stenosis accord-
ing to the European Carotid Surgery Trial criteria, hence
the degree of luminal narrowing would be estimated at
50% stenosis if the NASCET criteria were applied.42
The high concordance with histological findings in a
patient population similar to ours underlines the accuracy
of this imaging technique. Discrepancies in reported
prevalence from other in vivo MRI studies might be
explained by differences in the study population or lim-
ited sensitivity of the techniques. A higher sensitivity of
gradient echo over spin echo MRI for detection of PH
has been previously demonstrated.43 PH as defined by
MRI methods has been identified across a wide range of
carotid stenosis,44 and appears to be a feature of plaque
vulnerability across all degrees of luminal narrow-
ing,19,24,28–33 even in low-grade stenosis.34,45
To our knowledge, this is the largest longitudinal
MRI study of symptomatic carotid artery disease for pre-
diction of secondary events in vulnerable patients with a
follow-up of up to 9 years. The CIs around our estimate
rates of recurrent events were still wide, limited by the
number of observed recurrent events. However, the 95%
CI for the HR of recurrent cerebral ischemic events in
our MRIPH1 group, adjusted for known vascular risk
factors, suggests a minimum HR of 4.7. Notably, this
minimum HR carries a higher predictive value for recur-
rence than other identified clinical risk factors reported
from analysis of the results from the NASCET trial.
These clinical risk factors include age, sex, stroke being
the primary index event, and time period of <2 weeks
from the index event, all with HRs of <2.3.46 The pre-
dictive power of MRIPH also compares favorably with
other risk markers, namely cerebral microembolic signals
as detected by transcranial Doppler ultrasound, with a
reported lower bound of OR of 2 (OR5 4.7, 95%
CI5 2.0–11.0, p< 0.0001) for prediction of recurrent
stroke and TIA in 50% symptomatic carotid artery ste-
nosis.47 The MRI technique in our study was likewise
superior to another assessment tool, ultrasonographic
grading of carotid stenosis, with an HR of 12 for
MRIPH versus 1.9 for tighter stenosis.
MRIPH has significant potential for improved
patient selection, reduction of unnecessary treatment risk,
and cost-effective targeted intervention. Notably, we report
a cumulative observation period of 156.7 person-years in
patients without plaque hemorrhage on best medical treat-
ment only, that is, prior to CEA or study end, during
which only 1 stroke occurred (see Table 2). The nominal
annual absolute stroke risk of 0.6% is unlikely to outweigh
the risk of endarterectomy in many surgical centers. On
average, the postprocedural risk of stroke or death within
30 days of CEA or stenting is considered to be between
2.6 and 4.8%,48 with even lower rates for specialized cen-
ters; a post-CEA risk of 1.1% was recently reported for our
regional hospital services.49 Although we cannot exclude
the possibility that patients without MRIPH may also
have a lower perioperative risk of CEA, surgical interven-
tion in the very low-risk MRIPH negative group (0.6%
annual risk) might still pose an unacceptably high risk for
this subgroup of patients.
Oral medical treatments and CEA were offered to
all our study population for secondary prevention accord-
ing to national and local standard guidelines at the time,
and none of the treatments was altered or delayed for the
purpose of the studies.
The remarkably low risk of patients with absent
MRIPH provides a sound rationale for challenging the risk–
benefit assessment for carotid interventions in MRIPH2
patients with symptomatic carotid artery stenosis. This is
particularly true in subgroups already known to be at lower
risk of stroke, such as those presenting >2 weeks from the
initial event, female patients, and those with a moderate
degree of stenosis and/or high surgical risk. The observed
low risk of recurrent or first ipsilateral ischemic events in the
absence of MRIPH was not limited to our study popula-
tion, as confirmed by meta-analysis. A large-scale random-
ized controlled trial is, however, needed prior to
implementation of this biomarker in clinical practice.
The study is limited by a natural history study
design with the follow-up periods defined by scheduled
CEA for those patients who in accordance with concurrent
best clinical care in the United Kingdom at the time of
recruiting patients were offered CEA. A large proportion
of our patients (67%) underwent CEA with both the deci-
sion and timing of CEA based on independent clinical de-
cision making. The current treatment practice in our and
other UK centers has recently changed to offering CEA to
most patients with at least a 50% degree of stenosis. This
makes our reported data set unique and enabled us to
demonstrate the strong predictive value of MRIPH status
for recurrent events. Importantly, MRIPH status did not
affect treatment decisions, and hence we can rule out per-
tinent bias. Hence, patients with high-degree stenosis were
offered CEA and followed up only until scheduled CEA,
which led to shorter follow-up and higher rate of
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censoring in high-grade stenosis. We acknowledge that this
may have reduced the predictive power of the degree of
stenosis in our multivariate Cox model. Based on recruit-
ment and local audit numbers, we estimate that about
86% of the patient population of our vascular clinics were
recruited, which we consider a strength of the study, sug-
gesting that our findings can be considered representative
of a tertiary care TIA/stroke service population.
In summary, MRIPH is a strong and independent
predictor of risk of recurrent events in symptomatic ca-
rotid disease, which may help to assist patient selection
for carotid intervention in clinical scenarios with a
reduced risk–benefit ratio. The particularly low risk of
recurrent events in patients without MRIPH challenges
the current risk–benefit assessment for carotid interven-
tion and calls for a randomized controlled trial to assess
the benefit of intervention over best medical therapy for
patients with low- to intermediate-risk carotid disease,
stratified for presence or absence of plaque hemorrhage.
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